We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agilent Technologies and SomaLogic Enter Agreement
News

Agilent Technologies and SomaLogic Enter Agreement

Agilent Technologies and SomaLogic Enter Agreement
News

Agilent Technologies and SomaLogic Enter Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agilent Technologies and SomaLogic Enter Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The companies will initially place SomaLogic's SOMAscan proteomic assay, which employs custom Agilent microarrays in its workflow, in select academic and contract research centers. Although the SOMAscan assay is already available to researchers directly from SomaLogic as a service, this planned roll-out is aimed at meeting the rapidly growing demand for access to SomaLogic's highly multiplexed, cost-effective proteomic analyses.

"This agreement will greatly enhance our current microarray offerings by expanding them into the rapidly growing proteomics market," said Jacob Thaysen, vice president and general manager of Agilent's Genomics Solutions Division. "SomaLogic's cutting-edge proteomic technology makes them an ideal partner for us to increase our presence in this growing market."

"Agilent's custom microarrays have been a critical element in our development of the SOMAscan assay over the past several years," said Larry Gold, Ph.D., chairman and CEO of SomaLogic. "We are delighted that our partnership is expanding to make the technology even more accessible to researchers everywhere."

Terms of the agreement were not disclosed.


Advertisement